...
首页> 外文期刊>Pharmacogenomics >IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients
【24h】

IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients

机译:IL-1B rs1143623和EEF1A1P11-RPL7P9 rs10783050多态性影响中国超重或肥胖2型糖尿病患者二甲双胍的降糖功效

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: To investigate the potential genetic effect on metformin efficacy in overweight or obese Chinese Type 2 diabetes mellitus (T2DM) patients. Patients & methods: 768 SNPs in or close to 207 genes were genotyped in 84 patients treated with metformin + glibenclamide/Xiaoke Pill. Significant SNPs were then verified in 107 recent-onset overweight or obese T2DM patients treated with metformin alone. Genotyping was done by Illumina GoldenGate Assay. Results: In the discovery stage, 22 SNPs were nominally significant. IL1B rs1143623 (p = 0.011) and EEF1A1P11-RPL7P9 rs10783050 (p = 0.021) were still significantly associated with the relative change of HbA(1c) in the replication stage. Conclusion:IL1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms may contribute to metformin's glucose-lowing efficacy in overweight or obese Chinese T2DM patients.
机译:目的:研究超重或肥胖的中国2型糖尿病(T2DM)患者对二甲双胍疗效的潜在遗传效应。患者与方法:在84位接受二甲双胍+格列本脲/小克丸治疗的患者中对207个基因中或接近207个基因的768个SNP进行了基因分型。然后,在107名仅接受二甲双胍治疗的近期发作的超重或肥胖T2DM患者中证实了重要的SNP。基因分型由Illumina GoldenGate Assay完成。结果:在发现阶段,有22个SNP在名义上是重要的。 IL1B rs1143623(p = 0.011)和EEF1A1P11-RPL7P9 rs10783050(p = 0.021)在复制阶段仍与HbA(1c)的相对变化显着相关。结论:IL1B rs1143623和EEF1A1P11-RPL7P9 rs10783050多态性可能有助于二甲双胍对超重或肥胖中国T2DM患者的降糖功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号